跳至主要内容
临床试验/JPRN-jRCT2080221032
JPRN-jRCT2080221032未知2 期

A Multi-center, Randomized, Single-blind, Dose-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Doses of Adjuvanted Cell-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Japanese Pediatric Subjects

ovartis Pharma K.K.0 个研究点目标入组 120 人开始时间: 2010年3月2日最近更新:

试验速览

阶段
2 期
发起方
入组人数
120

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 至 <= 19age old(—)
性别
All

入选标准

  • Healthy Japanese aged 6 months to 19 years

排除标准

  • - History of anaphylaxis, serious vaccine reactions, hypersensitivity to vaccine viral proteins or excipients
  • - Administration of adjuvanted influenza vaccine or suspected influenza disease within 3 month prior to study start
  • - Administration of any other vaccines within 4 weeks prior to enrollment expect for seasonal influenza vaccines within 1 week
  • - History of progressive or severe neurological disorders

研究者

发起方
ovartis Pharma K.K.

相似试验

未知
2 期
A Multi-center, Randomized, Single-blind, Dose-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Doses of Adjuvanted Cell-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Japanese Adult Subjects
JPRN-jRCT2080221031ovartis Pharma K.K.200
进行中(未招募)
不适用
Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Pediatric Subjects
EUCTR2014-005075-88-Outside-EU/EEAovartis Pharma K.K120
进行中(未招募)
1 期
A Multi-Center, Double-Blind, Randomized, Dose-Ranging Study of the Safety and Efficacy of IDP-102 Gel 5 %, and 15 % Compared with Vehicle in the Treatment of Common Warts.common warts
EUCTR2005-002820-32-DEDow Pharmaceutical Sciences Inc.107
进行中(未招募)
不适用
A Randomized, Double-blinded, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination with Pegasys and Copegus versus the Currently Approved Combination of Pegasys and Copegus in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1 or 4 Virus Infection. - NDChronic Hepatitis C (CHC) Genotype 1 or 4MedDRA version: 12.1Level: LLTClassification code 10008912Term: Chronic hepatitis C
EUCTR2008-008258-21-ITF. Hoffmann - La Roche Ltd - Pharmaceutical Division, PDR400
进行中(未招募)
1 期
A Randomized, Double-blinded, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination with Pegasys® and Copegus® versus the Currently Approved Combination of Pegasys® and Copegus® in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1 or 4 Virus Infection.
EUCTR2008-008258-21-GBF. Hoffmann-La Roche Ltd400